首页> 外文期刊>International journal of geriatric psychiatry >An examination of the Boston Naming Test: calculation of 'estimated' 60-item score from 30- and 15-item scores in a cognitively impaired population.
【24h】

An examination of the Boston Naming Test: calculation of 'estimated' 60-item score from 30- and 15-item scores in a cognitively impaired population.

机译:波士顿命名测试的检查:在认知障碍的人群中,根据30和15个项目的得分计算“估计”的60个项目的得分。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Multiple versions of the Boston Naming Test (BNT) exist, which makes comparison of findings from different studies difficult. The current project sought to determine if estimated 60-item BNT scores could be reliably calculated from 30- and 15-item administrations with patients diagnosed with Alzheimer's disease (AD). METHODS: Estimated 60-item scores were created for 30-item (even and odd) and 15-item Consortium to Establish a Registry for Alzheimer's disease (CERAD) versions of the BNT from a database containing item-level responses for all BNT items. Correlations were conducted between all three estimated 60-item scores and full 60-item version scores administered to all participants in the sample. RESULTS: The estimated versions were all highly correlated with the standard 60-item version of the BNT across the sample and these findings held when the sample was separated out by case (AD) and control status. Mean difference scores were very small for scores estimated from 30-item administrations; however, difference scores for the 15-item CERAD were much larger. CONCLUSIONS: Estimated 60-item versions of the BNT can be created from 30-item BNT administrations, which will enable comparisons across studies and allow integration of data from various AD research groups for increased power in analytic protocols. Creation of an estimated score from the 15-item CERAD version is not warranted.
机译:目的:存在多种版本的波士顿命名测试(BNT),这使得比较不同研究的结果变得困难。当前的项目旨在确定,对于诊断为阿尔茨海默氏病(AD)的患者,从30和15个项目的给药中,能否可靠地估算出60个项目的BNT评分。方法:为30个项目(偶数和奇数)和15个项目联盟创建了估计的60个项目分数,以从包含所有BNT项目的项目级响应的数据库中建立BNT的阿尔茨海默氏病(CERAD)版本的注册表。在所有三个估计的60项评分与对样本中所有参与者进行的完整60项版本评分之间进行关联。结果:所有样本的估计版本均与BNT的标准60项版本高度相关,当按病例(AD)和对照状态分离样本时,这些发现将保持不变。从30个项目的管理中得出的平均得分差异很小。但是,15个项目的CERAD的差异分数要大得多。结论:可以从30个项目的BNT主管部门创建大约60个项目的BNT版本,这将使跨研究的比较成为可能,并允许集成来自各个AD研究小组的数据,以提高分析规程的功能。不保证从15个项目的CERAD版本中创建估算分数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号